<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical spectrum of antineutrophil cytoplasmic autoantibodies</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical spectrum of antineutrophil cytoplasmic autoantibodies</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical spectrum of antineutrophil cytoplasmic autoantibodies</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ronald J Falk, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter A Merkel, MD, MPH</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Glassock, MD, MACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gerald B Appel, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 03, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The relationship between antineutrophil cytoplasmic autoantibodies (ANCA) and granulomatosis polyangiitis (GPA), microscopic polyangiitis (MPA), and "renal-limited" vasculitis (pauci-immune glomerulonephritis without evidence of extrarenal disease) is well established [<a href="#rid1">1-4</a>]. ANCA are also present in a substantial subset (approximately 40 percent) of patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome, abbreviated as EGPA) [<a href="#rid5">5</a>]. ANCA testing plays a critical role in the diagnosis and classification of vasculitides, even as debate about their ultimate importance in the pathogenesis and pathophysiology of these conditions continues.</p><p>Following a brief discussion of certain technical issues related to the performance of ANCA assays, a review of the disease associations of ANCA and clinical utility of ANCA testing will be presented here. The role of ANCA in the pathogenesis of GPA and related vasculitides is discussed separately. (See  <a class="medical medical_review" href="/d/html/3074.html" rel="external">"Pathogenesis of antineutrophil cytoplasmic autoantibody-associated vasculitis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">TECHNIQUES TO DETECT ANCA</span><span class="headingEndMark"> — </span>Two types of antineutrophil cytoplasmic autoantibody (ANCA) assays are in wide use:</p><p class="bulletIndent1"><span class="glyph">●</span>Indirect immunofluorescence assay, using alcohol-fixed buffy coat leukocytes</p><p class="bulletIndent1"><span class="glyph">●</span>Enzyme-linked immunosorbent assay (ELISA), using purified specific antigens</p><p></p><p>Of these two techniques, the immunofluorescence assay is more sensitive, and the ELISA is more specific. The optimal approach to clinical testing for ANCA is therefore to perform both immunofluorescence, if available, and ELISA to detect antibodies against the vasculitis-specific target antigens [<a href="#rid6">6,7</a>]. However, in the United States, ANCA testing is not standardized, and therefore, the sensitivity and specificity will vary among laboratories; there are also no standardized reference values for normal ranges. Ultimately, standardized testing with a highly sensitive and specific ELISA may replace the strategy of immunofluorescence followed by ELISA [<a href="#rid8">8</a>]. (See <a class="local">'Pitfalls of interpreting immunofluorescence results'</a> below.)</p><p>In vasculitis, the two relevant target antigens are proteinase 3 (PR3) and myeloperoxidase (MPO). Both PR3 and MPO are located in cytoplasmic azurophilic granules of neutrophils and the peroxidase-positive lysosomes of monocytes. Antibodies with target specificities for PR3 and MPO are called "PR3-ANCA" and "MPO-ANCA," respectively.</p><p class="headingAnchor" id="H2017270790"><span class="h2">Indirect immunofluorescence test for ANCA</span></p><p class="headingAnchor" id="H3"><span class="h3">Immunofluorescence patterns in vasculitis</span><span class="headingEndMark"> — </span>When the sera of patients with ANCA-associated vasculitis are incubated with ethanol-fixed human neutrophils, two major immunofluorescence patterns are observed  (<a class="graphic graphic_picture graphicRef66748 graphicRef78968" href="/d/graphic/66748.html" rel="external">picture 1A-B</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>C-ANCA pattern</strong> – With the cytoplasmic ANCA (C-ANCA) pattern, the staining is diffuse throughout the cytoplasm. In most cases, antibodies directed against PR3 cause this pattern [<a href="#rid9">9,10</a>], but MPO-ANCA can occasionally be responsible.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>P-ANCA pattern</strong> – The perinuclear ANCA (P-ANCA) pattern results from a staining pattern around the nucleus, which represents an artifact of weak ethanol fixation. With ethanol fixation of the neutrophil substrate, positively charged granule constituents rearrange themselves around the negatively charged nuclear membrane, leading to perinuclear fluorescence [<a href="#rid3">3</a>]. Among patients with vasculitis, the antibody responsible for this pattern is usually directed against MPO (and only occasionally PR3).</p><p></p><p class="headingAnchor" id="H4"><span class="h3">Immunofluorescence patterns in nonvasculitic conditions</span><span class="headingEndMark"> — </span>Atypical ANCA patterns may be observed on immunofluorescence testing in patients with immune-mediated conditions other than systemic vasculitis (eg, connective tissue disorders, inflammatory bowel disease, and autoimmune hepatitis). These atypical ANCA patterns may be confused with P-ANCA patterns. However, ELISA testing for antibodies against MPO or PR3 is negative in such cases.</p><p class="headingAnchor" id="H5"><span class="h3">Pitfalls of interpreting immunofluorescence results</span><span class="headingEndMark"> — </span>For several reasons, caution is required in the interpretation of both positive and negative C- and P-ANCA immunofluorescence patterns:</p><p class="bulletIndent1"><span class="glyph">●</span>There is a subjective component to the interpretation of immunofluorescence assays because the tests are based upon visual interpretation of the immunofluorescence pattern; this is sometimes not straightforward. Thus, the positive or negative predictive value of a given test result depends upon the experience of the individual who performs the assay. The positive and negative predictive values are likely to be better with results from a research laboratory than with a commercial assay, but variability exists in all laboratories [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ANCA testing remains unstandardized in the United States, and there are no references for normal ranges. In evaluating the utility of ANCA testing in clinical practice, it must be borne in mind that most studies of ANCA serologies have been performed at tertiary care centers using research laboratories focused on ANCA testing. Translating the test characteristics from the environments of research laboratories to clinical practice must be done with caution.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunofluorescence results are not highly specific for the diagnosis of vasculitis. The C-ANCA pattern has a greater specificity than the P-ANCA pattern for vasculitis. (See <a class="local">'Disease associations'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antibodies to a host of azurophilic granule proteins can cause a P-ANCA staining pattern. These include antibodies directed against lactoferrin, elastase, cathepsin G, bactericidal/permeability-increasing protein (BPI), catalase, lysozyme, beta-glucuronidase, and others. A positive P-ANCA immunofluorescence staining pattern may also be detected in a wide variety of inflammatory illnesses and has a low specificity for vasculitis. A positive immunofluorescence assay should therefore always prompt testing by ELISA to determine the specific antibody (or antibodies) responsible for the pattern.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Because of the frequent difficulty in distinguishing the P-ANCA pattern of immunofluorescence from that caused by antinuclear antibodies (ANA), individuals with ANA frequently have "false-positive" results on ANCA testing by immunofluorescence. Typically, in patients who have a positive ANA, a positive P-ANCA is a false positive. However, pauci-immune necrotizing glomerulonephritis has been reported in patients with systemic lupus erythematosus (SLE) with positive P-ANCA, and ELISA testing should be performed in all such patients [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>To avoid false-positive P-ANCA tests, immunofluorescence assays should be routinely performed on both formalin- and ethanol-fixed substrates. This is because formalin-fixed neutrophils prevent the rearrangement of charged cellular components around the nucleus. The use of both cell substrates permits the distinction between antibodies causing a "true" P-ANCA pattern and those directed against the nuclear antigens (ANA). (See  <a class="medical medical_review" href="/d/html/1822.html" rel="external">"Measurement and clinical significance of antinuclear antibodies"</a>.)</p><p></p><p class="headingAnchor" id="H6"><span class="h2">Solid-phase immunoassays</span><span class="headingEndMark"> — </span>Solid-phase immunoassays (eg, ELISAs) are used for detection of specific antibodies to PR3 and MPO are commercially available and should be part of any standardized approach to the testing for ANCA. ELISAs are the most commonly used solid-phase assay but alternative solid-phase assays are also available [<a href="#rid8">8</a>].</p><p>PR3-ANCA and MPO-ANCA are associated with substantially higher specificities and positive predictive values than the immunofluorescence patterns to which they usually correspond (C- and P-ANCA, respectively) [<a href="#rid13">13</a>]. However, errors can be made if these tests are not performed in experienced laboratories. ELISAs for other antigens are also available, but the indications for their use are unclear.</p><p class="headingAnchor" id="H7"><span class="h1">DISEASE ASSOCIATIONS</span></p><p class="headingAnchor" id="H2654479157"><span class="h2">ANCA-associated vasculitis</span><span class="headingEndMark"> — </span>Antineutrophil cytoplasmic autoantibodies (ANCA) are associated with granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss), "renal-limited" vasculitis, and certain drug-induced vasculitis syndromes [<a href="#rid14">14</a>]. In these conditions, ANCA consistently have specificities for either proteinase 3 (PR3) or myeloperoxidase (MPO) but almost never for both.</p><p class="headingAnchor" id="H8"><span class="h3">Granulomatosis with polyangiitis</span><span class="headingEndMark"> — </span>Approximately 90 percent of patients with active, generalized GPA are ANCA positive. However, a small subset of patients with active, generalized GPA or more limited forms of the disease do not have ANCA (such as a subset of patients with predominantly upper respiratory tract disease and no kidney involvement). Thus, the absence of ANCA does not exclude the diagnosis of GPA. In large measure, the sensitivity of PR3-ANCA for GPA is related to activity of disease at the time of sampling [<a href="#rid15">15</a>].</p><p>Among patients who have GPA with ANCA, 80 to 90 percent have PR3-ANCA. The remainder of ANCA-positive GPA patients have MPO-ANCA. Necrotizing granulomatous inflammation, the histopathologic hallmark of GPA, has been reported in both PR3- and MPO-ANCA-positive individuals. (See  <a class="medical medical_review" href="/d/html/3074.html" rel="external">"Pathogenesis of antineutrophil cytoplasmic autoantibody-associated vasculitis"</a> and  <a class="medical medical_review" href="/d/html/3117.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Clinical manifestations and diagnosis", section on 'Testing for ANCA'</a> and  <a class="medical medical_review" href="/d/html/3117.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Clinical manifestations and diagnosis", section on 'Histopathology'</a>.)</p><p class="headingAnchor" id="H9"><span class="h3">Microscopic polyangiitis</span><span class="headingEndMark"> — </span>Nearly 90 percent of patients with MPA are ANCA positive [<a href="#rid16">16</a>]. In contrast to GPA, most ANCA-positive patients with MPA have MPO-ANCA, with a minority having PR3-ANCA. Because PR3-ANCA or MPO-ANCA may occur in both GPA and MPA, these diseases cannot be distinguished on the basis of ANCA specificity. Data pertaining to ANCA and MPA are also complicated by the lack of consensus concerning the definition of MPA. The distinction between GPA and MPA is important chiefly because of differential tendencies to flare. Although both diseases may flare after the achievement of remission, GPA is substantially more likely to relapse [<a href="#rid17">17-19</a>]. (See  <a class="medical medical_review" href="/d/html/3040.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Management of relapsing disease", section on 'Risk factors for relapse'</a> and  <a class="medical medical_review" href="/d/html/3071.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Management of disease resistant to initial therapy", section on 'Incidence and risk factors'</a>.)</p><p class="headingAnchor" id="H10"><span class="h3">Renal-limited vasculitis</span><span class="headingEndMark"> — </span>Pauci-immune vasculitis limited to the kidney is characterized by necrotizing glomerulonephritis with little or no deposition of immunoreactants (immunoglobulin G [IgG], immunoglobulin M [IgM], immunoglobulin A [IgA], and complement components). The majority of patients with renal-limited vasculitis are ANCA positive, with 75 to 80 percent having MPO-ANCA.</p><p>ANCA-positive pauci-immune necrotizing glomerulonephritis is considered to be part of the GPA/MPA spectrum because the histopathologic findings in the kidney are indistinguishable from those of the glomerulonephritis in GPA or MPA and because some patients who present with disease limited to the kidney eventually exhibit extrarenal manifestations of either GPA or MPA [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/d/html/3117.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Clinical manifestations and diagnosis", section on 'Establishing the diagnosis'</a>.)</p><p class="headingAnchor" id="H11"><span class="h3">Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)</span><span class="headingEndMark"> — </span>ANCA, both PR3 and MPO, have been detected with variable frequencies in patients with EGPA [<a href="#rid21">21-26</a>]. Although variable from study to study, approximately 30 to 50 percent of patients with EGPA are ANCA positive, with the percentage being somewhat higher in those with active, untreated disease [<a href="#rid5">5,24</a>]. Among patients with ANCA-positive EGPA, MPO-ANCA is substantially more frequent than PR3-ANCA. As an example, in one series, 40 of 102 patients with EGPA were ANCA positive, and 29 (73 percent) had specificity for MPO-ANCA [<a href="#rid26">26</a>]. In a second study, 38 of 43 ANCA-positive patients with EGPA were tested for MPO and PR3; MPO was identified in 34 patients (79 percent), and PR3 was identified in none [<a href="#rid5">5</a>].</p><p>Some studies suggest the possibility of clinical differences among patients with EGPA who are ANCA positive compared with those who are ANCA negative [<a href="#rid5">5,25,27</a>]. ANCA-positive patients are more likely to have glomerulonephritis, alveolar hemorrhage, and neurologic disease, whereas ANCA-negative patients are more likely to have cardiac and other pulmonary involvement. However, there is certainly overlap in clinical presentations among patients with and without ANCA (as is true in GPA and MPA). (See  <a class="medical medical_review" href="/d/html/4363.html" rel="external">"Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)"</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Anti-GBM autoantibody disease</span><span class="headingEndMark"> — </span>Between 10 and 50 percent of patients with anti-glomerular basement membrane (GBM) autoantibody disease are ANCA positive at the time of diagnosis, and ANCA is usually directed against MPO rather than PR3 [<a href="#rid28">28-33</a>]. In general, patients who are positive for both anti-GBM autoantibodies and ANCA have a higher risk of relapse than patients positive only for anti-GBM autoantibodies. In such "double-positive" patients, the initial clinical presentation is often similar to patients with isolated anti-GBM disease, whereas relapses are usually characteristic of patients with isolated ANCA-associated vasculitis. A detailed discussion of double-positive anti-GBM and ANCA-associated disease can be found elsewhere. (See  <a class="medical medical_review" href="/d/html/3108.html" rel="external">"Anti-GBM (Goodpasture) disease: Pathogenesis, clinical manifestations, and diagnosis", section on 'Double-positive anti-GBM and ANCA-associated disease'</a>.)</p><p>In patients with both ANCA and anti-GBM autoantibodies, the relationship between the two antibodies is unknown. The antigen specificity for the anti-GBM autoantibodies is the same as in patients with anti-GBM autoantibody disease alone, suggesting that the inciting antigen is the same [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H13"><span class="h2">Drug-induced ANCA-associated vasculitis</span><span class="headingEndMark"> — </span>Certain medications may induce forms of vasculitis associated with ANCA. Most patients reported with drug-induced ANCA-associated vasculitis have MPO-ANCA, frequently in very high titers [<a href="#rid34">34</a>]. A small number have PR3-ANCA.</p><p>Many cases of drug-induced ANCA-associated vasculitis are associated with constitutional symptoms, arthralgias/arthritis, and cutaneous vasculitis. However, the full range of clinical features associated with ANCA, including crescentic glomerulonephritis and alveolar hemorrhage, can also occur.</p><p>The strongest links between medications and ANCA-associated vasculitis are with drugs employed in the treatment of hyperthyroidism (<a class="drug drug_general" data-topicid="9830" href="/d/drug information/9830.html" rel="external">propylthiouracil</a>, <a class="drug drug_general" data-topicid="9627" href="/d/drug information/9627.html" rel="external">methimazole</a> [thiamazole], and carbimazole), <a class="drug drug_general" data-topicid="8528" href="/d/drug information/8528.html" rel="external">hydralazine</a>, and <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a>. Of these, hydralazine is the most common cause of drug-induced ANCA-associated vasculitis [<a href="#rid35">35</a>]. As discussed below, many cases of "drug-induced lupus" are actually drug-induced ANCA-associated vasculitis. Other implicated drugs in clinical use include <a class="drug drug_general" data-topicid="91794" href="/d/drug information/91794.html" rel="external">sofosbuvir</a>, <a class="drug drug_general" data-topicid="8439" href="/d/drug information/8439.html" rel="external">allopurinol</a>, <a class="drug drug_general" data-topicid="9747" href="/d/drug information/9747.html" rel="external">penicillamine</a>, <a class="drug drug_general" data-topicid="9813" href="/d/drug information/9813.html" rel="external">procainamide</a>, <a class="drug drug_general" data-topicid="9289" href="/d/drug information/9289.html" rel="external">clozapine</a>, <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, rifampicin, <a class="drug drug_general" data-topicid="9221" href="/d/drug information/9221.html" rel="external">cefotaxime</a>, <a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a>, and <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> [<a href="#rid36">36-42</a>]. However, causal associations between these drugs and ANCA-associated vasculitis are not well established.</p><p>Drug-induced ANCA-associated vasculitis is sufficiently uncommon that the possibility of this complication should not preclude the use of medications associated with this condition. Clinicians frequently utilizing these medications should be aware of the potential for the development of ANCA-associated vasculitis. The detection of ANCA among patients taking these medications should prompt an evaluation to determine if vasculitis is present; the clinical differentiation between drug-induced "seropositivity" and drug-induced disease can be difficult to ascertain.</p><p class="headingAnchor" id="H1375040014"><span class="h3">Hydralazine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8528" href="/d/drug information/8528.html" rel="external">Hydralazine</a> has been associated with two drug-induced systemic rheumatic syndromes:</p><p class="bulletIndent1"><span class="glyph">●</span>Drug-induced lupus (see  <a class="medical medical_review" href="/d/html/4677.html" rel="external">"Drug-induced lupus"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Drug-induced ANCA-associated vasculitis, which is a potentially more serious condition</p><p></p><p>Unlike drug-induced lupus caused by <a class="drug drug_general" data-topicid="8528" href="/d/drug information/8528.html" rel="external">hydralazine</a>, hydralazine-induced ANCA-associated vasculitis is frequently associated with kidney involvement (usually a pauci-immune glomerulonephritis), antibodies to double-stranded DNA, and high titers of MPO-ANCA, as well as anti-histone antibodies and hypocomplementemia; patients generally require immunosuppressive therapy in addition to withdrawal of hydralazine [<a href="#rid34">34,43,44</a>]. In the largest series including 80 cases of hydralazine-induced ANCA-associated glomerulonephritis, extrarenal involvement was uncommon (18 percent with pulmonary involvement, 4 percent with purpura, 3 percent with upper airway involvement) [<a href="#rid45">45</a>]. On kidney biopsy, the predominant pattern on light microscopy was necrotizing and crescentic glomerulonephritis; however, compared with primary ANCA glomerulonephritis, the biopsies were less frequently pauci-immune on immunofluorescence and had more frequent mesangial hypercellularity, detectable electron dense deposits, and endothelial tubuloreticular inclusions. More than three-fourths of patients were on hydralazine for over 12 months. Among the 51 patients who had clinical follow-up, 42 patients received immunosuppressive therapy (including glucocorticoids, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, and/or <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a>) with or without plasmapheresis; all discontinued hydralazine. Fourteen patients (27 percent) progressed to end-stage kidney disease (ESKD), and 11 (21 percent) died; these outcomes are similar to those of patients with primary ANCA-associated glomerulonephritis treated with standard therapy [<a href="#rid46">46,47</a>]. (See  <a class="medical medical_review" href="/d/html/3105.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Drug-induced ANCA-associated vasculitis'</a>.)</p><p class="headingAnchor" id="H14"><span class="h3">Propylthiouracil</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9830" href="/d/drug information/9830.html" rel="external">Propylthiouracil</a> may be the most common offending agent in drug-induced ANCA seropositivity. In general, patients with this complication have taken the medication for months or even years. A relatively high percentage of patients administered propylthiouracil develop ANCA. In a cross-sectional study, for example, 27 percent of patients receiving long-term treatment with propylthiouracil developed MPO-ANCA seropositivity [<a href="#rid48">48</a>]. However, only a small proportion of such patients develop clinical vasculitis. In another study of 209 patients with hyperthyroidism, 13 (6 percent) were positive for either MPO- or PR3-ANCA or for ANCA directed against human leukocyte elastase [<a href="#rid49">49</a>]. The presence of ANCA was highly associated with treatment with propylthiouracil and related antithyroid drugs (odds ratio [OR] 11.8, 95% CI 1.5-93.3). ANCA positivity with glomerulonephritis developed in approximately one-third (4 of 13).</p><p>Although the mechanism of ANCA seropositivity and vasculitis caused by <a class="drug drug_general" data-topicid="9830" href="/d/drug information/9830.html" rel="external">propylthiouracil</a> has not been well defined, it is known that propylthiouracil accumulates in neutrophils and that it binds to and alters the MPO antigen [<a href="#rid50">50,51</a>]. This alteration could potentially lead to the formation of autoantibodies in susceptible individuals.</p><p>In patients who develop a vasculitis, the syndrome often resolves with discontinuation of <a class="drug drug_general" data-topicid="9830" href="/d/drug information/9830.html" rel="external">propylthiouracil</a>, but severe cases may require treatment with glucocorticoids and other immunosuppressive medications. ANCA titers do not usually persist after active vasculitis has abated. (See  <a class="medical medical_review" href="/d/html/3105.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Drug-induced ANCA-associated vasculitis'</a>.)</p><p class="headingAnchor" id="H16"><span class="h3">Minocycline</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">Minocycline</a> has been associated with arthritis, fever, livedo reticularis, and the induction of ANCA in a report of seven patients [<a href="#rid52">52</a>]. The perinuclear ANCA (P-ANCA) immunofluorescence pattern typically associated with this disorder is usually directed against minor antigens such as cathepsin G, elastase, and bactericidal/permeability-increasing protein (BPI) rather than against MPO [<a href="#rid52">52,53</a>]. Symptoms typically resolve with the cessation of minocycline therapy and recur with drug rechallenge. Some patients require treatment with glucocorticoids.</p><p>More serious manifestations of an ANCA-positive vasculitis have been described in association with <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a> therapy, including crescentic glomerulonephritis, a lupus-like syndrome, and cutaneous polyarteritis nodosa (PAN) [<a href="#rid54">54-57</a>].</p><p class="headingAnchor" id="H2119946435"><span class="h3">Cocaine and levamisole</span><span class="headingEndMark"> — </span>Approximately 70 percent of cocaine bought illicitly in the United States is contaminated or "cut" with levamisole, an anti-helminthic agent with immunomodulatory properties. The use of levamisole-contaminated cocaine is associated with ANCA vasculitis, which can cause a unique vasculopathy associated with gangrenous skin lesions [<a href="#rid58">58-63</a>]. Levamisole exposure is associated with "dual positivity" for PR3- and MPO-ANCA. One of the largest series described 30 patients who presented between 2009 and 2010 [<a href="#rid58">58</a>]. The most common clinical manifestations included arthralgias (83 percent) and skin lesions (61 percent). Seventy-two percent of patients reported fever, night sweats, weight loss, myalgias, or other constitutional symptoms. All patients had a positive MPO-ANCA, and 50 percent also had a positive PR3-ANCA. Twenty-eight percent of patients had leukopenia. An abnormal urinalysis (including proteinuria, hematuria, or cellular casts) was present in eight patients, and two patients developed pulmonary hemorrhage.</p><p>Levamisole is occasionally used as a glucocorticoid-sparing agent for the management of nephrotic syndrome in children; its availability is limited worldwide, and it is only approved by the US Food and Drug Administration (FDA) as an anti-helminthic agent. A cohort study including 71 children taking levamisole for nephrotic syndrome found that 12 out of 33 patients tested were positive for ANCA [<a href="#rid64">64</a>]. Only 2 of these 12 patients developed clinical findings suggestive of ANCA-associated vasculitis resulting in discontinuation of levamisole. (See  <a class="medical medical_review" href="/d/html/6130.html" rel="external">"Treatment of idiopathic nephrotic syndrome in children", section on 'Levamisole'</a>.)</p><p class="headingAnchor" id="H18"><span class="h2">Interstitial nephritis</span><span class="headingEndMark"> — </span>Interstitial nephritis may be seen with ANCA-associated vasculitis when the vasculitis involves the renal medulla [<a href="#rid39">39,40</a>]. In addition, acute drug-induced interstitial nephritis has occasionally been associated with ANCA formation, with the ANCA reacting against MPO, elastase, and lactoferrin [<a href="#rid65">65</a>]. (See  <a class="medical medical_review" href="/d/html/7234.html" rel="external">"Clinical manifestations and diagnosis of acute interstitial nephritis", section on 'Establishing the cause'</a>.)</p><p class="headingAnchor" id="H19"><span class="h2">Nonvasculitic systemic rheumatic diseases</span><span class="headingEndMark"> — </span>ANCA have been reported in virtually all systemic rheumatic diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Sjögren's disease, inflammatory myopathies, juvenile chronic arthritis, reactive arthritis, relapsing polychondritis, systemic sclerosis, and the antiphospholipid syndrome. In most cases, the immunofluorescence pattern is P-ANCA. Atypical fluorescence patterns also occur in these settings, while cytoplasmic ANCA (C-ANCA) patterns are rare. The clinical significance of the presence of ANCA in these disorders is unclear. Many reports of ANCA in these diseases preceded the availability of reliable enzyme-linked immunosorbent assays (ELISAs) for PR3- and MPO-ANCA, and ANCA were detected with only immunofluorescence assays. When tested for ANCA using both immunofluorescence and ELISA methods, many of these patients with a positive test for ANCA by immunofluorescence had a negative test for ANCA by ELISA [<a href="#rid11">11</a>]. A multitude of target antigens has been described in patients with these disorders, including lactoferrin, elastase, lysozyme, cathepsin G, and others. In some cases, the specific target antigen remains to be identified.</p><p class="headingAnchor" id="H20"><span class="h2">Autoimmune gastrointestinal disorders</span><span class="headingEndMark"> — </span>ANCA positivity is seen in 60 to 80 percent of patients with ulcerative colitis and the related disorder primary sclerosing cholangitis. It is observed in only 10 to 27 percent of patients with Crohn disease, in whom only low titers are present.</p><p>The P-ANCA in these conditions appears to be predominantly directed against a myeloid cell-specific 50 kilodalton nuclear envelope protein [<a href="#rid66">66</a>]. Other reported antigen targets include BPI, lactoferrin, cathepsin G, elastase, lysozyme, and PR3 [<a href="#rid67">67</a>].</p><p>The pathogenetic significance of these antibodies is unclear. The titers of ANCA do not vary with the activity or severity of the disease and, in ulcerative colitis, do not fall after colectomy.</p><p class="headingAnchor" id="H21"><span class="h2">Cystic fibrosis</span><span class="headingEndMark"> — </span>Non-MPO P-ANCA are common in patients with cystic fibrosis, particularly among those with bacterial airway infections [<a href="#rid68">68,69</a>]. The ANCA is directed against BPI [<a href="#rid68">68</a>], with a strong association with <em>Pseudomonas aeruginosa</em> infection and colonization [<a href="#rid70">70</a>]. BPI is a potent antimicrobial factor of the innate defense, which is present in the azurophilic granules of neutrophils [<a href="#rid71">71</a>]. In one series of 66 patients with cystic fibrosis, BPI-IgG- and BPI-IgA-ANCA were found in 91 and 83 percent, respectively [<a href="#rid68">68</a>]. Anti-BPI titers were directly related to the severity of airway destruction. It is unclear whether this relationship represents an epiphenomenon or a response (adaptive or maladaptive) to gram-negative infection with release of endotoxin.</p><p class="headingAnchor" id="H1212699933"><span class="h2">Infections</span><span class="headingEndMark"> — </span>Positive tests for ANCA, especially C-ANCA and PR3-ANCA, have been reported in patients with subacute bacterial endocarditis and other forms of bacteremia [<a href="#rid72">72-75</a>]. In a large series from France in which stored serum specimens from patients with bacteremia were later tested for ANCA, 18 percent of patients had positive tests for ANCA by immunofluorescence, and 8 percent were positive for PR3- or MPO-ANCA by ELISA [<a href="#rid74">74</a>]. These data should prompt clinicians to have a low threshold to obtain blood cultures in patients with possible ANCA-associated vasculitis and in patients testing positive for ANCA.</p><p>De novo ANCA-associated vasculitis has been reported in the setting of coronavirus disease 2019 (COVID-19) [<a href="#rid76">76</a>] as well as following administration of <a class="drug drug_general" data-topicid="130318" href="/d/drug information/130318.html" rel="external">COVID-19 mRNA vaccines</a> [<a href="#rid77">77,78</a>]. However, the degree, if any, that SARS-CoV2 infection or vaccines targeting the virus are causal for vasculitis is not known. (See  <a class="medical medical_review" href="/d/html/127552.html" rel="external">"COVID-19: Issues related to acute kidney injury, glomerular disease, and hypertension", section on 'Glomerular disease'</a> and  <a class="medical medical_review" href="/d/html/127933.html" rel="external">"COVID-19: Care of adult patients with systemic rheumatic disease", section on 'COVID-19 as a risk factor for rheumatologic disease'</a>.)</p><p>Some but not all studies have identified ANCA positivity in patients with mycobacterium tuberculosis [<a href="#rid79">79-81</a>], leprosy, acute parvovirus B19 infection, acute infectious mononucleosis, malaria, and aspergillosis [<a href="#rid82">82,83</a>].</p><p class="headingAnchor" id="H4224614383"><span class="h2">Other concurrent glomerular diseases</span><span class="headingEndMark"> — </span>In addition to anti-GBM autoantibody disease, ANCA-associated glomerular disease has also been described to coexist with a variety of other glomerular diseases including membranous nephropathy, lupus nephritis, IgA nephropathy, and bacterial infection-related glomerulonephritis (mostly poststreptococcal and <em>Staphylococcus</em> associated). This issue is reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/3117.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Clinical manifestations and diagnosis", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H22"><span class="h2">Other possible associations</span><span class="headingEndMark"> — </span>In addition to the above disease associations, ANCA has also been observed in isolated patients with autoimmune hepatitis, thromboangiitis obliterans (Buerger's disease), preeclampsia and eclampsia, diffuse alveolar hemorrhage, chronic graft-versus-host disease, and cocaine-induced osteochondral destruction (cocaine-induced midline destructive lesions) [<a href="#rid84">84-89</a>].</p><p class="headingAnchor" id="H424851931"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110250.html" rel="external">"Society guideline links: Glomerular disease in adults"</a> and  <a class="medical medical_society_guidelines" href="/d/html/110743.html" rel="external">"Society guideline links: Vasculitis"</a>.)</p><p class="headingAnchor" id="H29"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Techniques to detect ANCA</strong> – Two types of antineutrophil cytoplasmic autoantibody (ANCA) assays are in wide use: indirect immunofluorescence assay and enzyme-linked immunosorbent assay (ELISA). In vasculitis, the two relevant target antigens detected by ELISA are proteinase 3 (PR3) and myeloperoxidase (MPO). Specific ELISAs for antibodies to PR3 and MPO are commercially available and should be part of any standardized approach to the testing for ANCA. PR3-ANCA and MPO-ANCA are associated with substantially higher specificities and positive predictive values than the immunofluorescence patterns to which they usually correspond (cytoplasmic ANCA [C-ANCA] and perinuclear ANCA [P-ANCA], respectively). (See <a class="local">'Techniques to detect ANCA'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease associations</strong> – ANCA are associated with a variety of disorders (see <a class="local">'Disease associations'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Granulomatosis with polyangiitis (GPA)</strong> – Approximately 90 percent of patients with active, generalized GPA are ANCA positive. Among patients who have GPA with ANCA, 80 to 90 percent have PR3-ANCA. (See <a class="local">'Granulomatosis with polyangiitis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Microscopic polyangiitis (MPA)</strong> – Nearly 90 percent of patients with MPA are ANCA positive, and most ANCA-positive patients with MPA have MPO-ANCA. (See <a class="local">'Microscopic polyangiitis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Renal-limited vasculitis</strong> – The majority of patients with renal-limited vasculitis are ANCA positive, with 75 to 80 percent having MPO-ANCA. (See <a class="local">'Renal-limited vasculitis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss)</strong> – ANCA, both PR3 and MPO, have been detected with variable frequencies in patients with EGPA. Among such patients, the vast majority have MPO-ANCA. (See <a class="local">'Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Anti-glomerular basement membrane (GBM) autoantibody disease</strong> – Between 10 and 50 percent of patients with anti-GBM autoantibody disease are ANCA positive at the time of diagnosis, and ANCA is usually directed against MPO rather than PR3. In addition to anti-GBM autoantibody disease, ANCA-associated glomerular disease has also been described to coexist with a variety of other disorders including membranous nephropathy, lupus nephritis, IgA nephropathy, and bacterial infection-related glomerulonephritis (mostly poststreptococcal and <em>Staphylococcus</em> associated). (See <a class="local">'Anti-GBM autoantibody disease'</a> above and <a class="local">'Other concurrent glomerular diseases'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Drug-induced ANCA-associated vasculitis </strong>– Certain medications may induce forms of vasculitis associated with ANCA (mostly MPO-ANCA), including <a class="drug drug_general" data-topicid="8528" href="/d/drug information/8528.html" rel="external">hydralazine</a>, <a class="drug drug_general" data-topicid="9830" href="/d/drug information/9830.html" rel="external">propylthiouracil</a>, <a class="drug drug_general" data-topicid="9627" href="/d/drug information/9627.html" rel="external">methimazole</a>, carbimazole, and <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a>. Other drugs, such as <a class="drug drug_general" data-topicid="8439" href="/d/drug information/8439.html" rel="external">allopurinol</a>, <a class="drug drug_general" data-topicid="9747" href="/d/drug information/9747.html" rel="external">penicillamine</a>, <a class="drug drug_general" data-topicid="9813" href="/d/drug information/9813.html" rel="external">procainamide</a>, thiamazole, <a class="drug drug_general" data-topicid="9289" href="/d/drug information/9289.html" rel="external">clozapine</a>, <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, rifampicin, <a class="drug drug_general" data-topicid="9221" href="/d/drug information/9221.html" rel="external">cefotaxime</a>, <a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a>, and <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a>, have less certain causal associations with ANCA-associated vasculitis. Levamisole-contaminated cocaine is also associated with drug-induced ANCA-associated vasculitis. (See <a class="local">'Drug-induced ANCA-associated vasculitis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other</strong> – ANCA may also be seen with interstitial nephritis, nonvasculitic systemic rheumatic diseases, autoimmune gastrointestinal disorders (such as ulcerative colitis), cystic fibrosis, and various infections. (See <a class="local">'Nonvasculitic systemic rheumatic diseases'</a> above and <a class="local">'Autoimmune gastrointestinal disorders'</a> above and <a class="local">'Cystic fibrosis'</a> above and <a class="local">'Infections'</a> above.)</p><p></p><p class="headingAnchor" id="H96738722"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>UpToDate thanks Dr. John H. Stone, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Davies DJ, Moran JE, Niall JF, Ryan GB. Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br Med J (Clin Res Ed) 1982; 285:606.</a></li><li><a class="nounderline abstract_t">van der Woude FJ, Rasmussen N, Lobatto S, et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985; 1:425.</a></li><li><a class="nounderline abstract_t">Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 1988; 318:1651.</a></li><li><a class="nounderline abstract_t">Tervaert JW, Goldschmeding R, Elema JD, et al. Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis. Kidney Int 1990; 37:799.</a></li><li><a class="nounderline abstract_t">Sablé-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005; 143:632.</a></li><li><a class="nounderline abstract_t">Hagen EC, Andrassy K, Csernok E, et al. Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA). A report on the second phase of an international cooperative study on the standardization of ANCA assays. J Immunol Methods 1996; 196:1.</a></li><li><a class="nounderline abstract_t">Hagen EC, Daha MR, Hermans J, et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int 1998; 53:743.</a></li><li><a class="nounderline abstract_t">Bossuyt X, Cohen Tervaert JW, Arimura Y, et al. Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol 2017; 13:683.</a></li><li><a class="nounderline abstract_t">Jennette JC, Wilkman AS, Falk RJ. Diagnostic predictive value of ANCA serology. Kidney Int 1998; 53:796.</a></li><li><a class="nounderline abstract_t">Niles JL, Pan GL, Collins AB, et al. Antigen-specific radioimmunoassays for anti-neutrophil cytoplasmic antibodies in the diagnosis of rapidly progressive glomerulonephritis. J Am Soc Nephrol 1991; 2:27.</a></li><li><a class="nounderline abstract_t">Merkel PA, Polisson RP, Chang Y, et al. Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease. Ann Intern Med 1997; 126:866.</a></li><li><a class="nounderline abstract_t">Nasr SH, D'Agati VD, Park HR, et al. Necrotizing and crescentic lupus nephritis with antineutrophil cytoplasmic antibody seropositivity. Clin J Am Soc Nephrol 2008; 3:682.</a></li><li><a class="nounderline abstract_t">Csernok E, Holle J, Hellmich B, et al. Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis: first results from a multicentre study. Rheumatology (Oxford) 2004; 43:174.</a></li><li><a class="nounderline abstract_t">Seo P, Stone JH. The antineutrophil cytoplasmic antibody-associated vasculitides. Am J Med 2004; 117:39.</a></li><li><a class="nounderline abstract_t">Hoffman GS, Specks U. Antineutrophil cytoplasmic antibodies. Arthritis Rheum 1998; 41:1521.</a></li><li><a class="nounderline abstract_t">Guillevin L, Durand-Gasselin B, Cevallos R, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999; 42:421.</a></li><li><a class="nounderline abstract_t">Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349:36.</a></li><li><a class="nounderline abstract_t">Schirmer JH, Wright MN, Vonthein R, et al. Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort. Rheumatology (Oxford) 2016; 55:71.</a></li><li><a class="nounderline abstract_t">Lionaki S, Blyth ER, Hogan SL, et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum 2012; 64:3452.</a></li><li><a class="nounderline abstract_t">Woodworth TG, Abuelo JG, Austin HA 3rd, Esparza A. Severe glomerulonephritis with late emergence of classic Wegener's granulomatosis. Report of 4 cases and review of the literature. Medicine (Baltimore) 1987; 66:181.</a></li><li><a class="nounderline abstract_t">Hauschild S, Schmitt WH, Csernok E, et al. ANCA in systemic vasculitides, collagen vascular diseases, rheumatic disorders and inflammatory bowel diseases. Adv Exp Med Biol 1993; 336:245.</a></li><li><a class="nounderline abstract_t">Tervaert JW, Kallenberg CG. Anti-myeloperoxidase antibodies in Churg-Strauss syndrome. J Neurol 1993; 240:449.</a></li><li><a class="nounderline abstract_t">Guillevin L, Cohen P, Gayraud M, et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999; 78:26.</a></li><li><a class="nounderline abstract_t">Keogh KA, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 2003; 115:284.</a></li><li><a class="nounderline abstract_t">Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005; 52:2926.</a></li><li><a class="nounderline abstract_t">Sinico RA, Di Toma L, Maggiore U, et al. Renal involvement in Churg-Strauss syndrome. Am J Kidney Dis 2006; 47:770.</a></li><li><a class="nounderline abstract_t">Doubelt I, Cuthbertson D, Carette S, et al. Clinical Manifestations and Long-Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America. ACR Open Rheumatol 2021; 3:404.</a></li><li><a class="nounderline abstract_t">Jayne DR, Marshall PD, Jones SJ, Lockwood CM. Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. Kidney Int 1990; 37:965.</a></li><li><a class="nounderline abstract_t">Hellmark T, Niles JL, Collins AB, et al. Comparison of anti-GBM antibodies in sera with or without ANCA. J Am Soc Nephrol 1997; 8:376.</a></li><li><a class="nounderline abstract_t">Weber MF, Andrassy K, Pullig O, et al. Antineutrophil-cytoplasmic antibodies and antiglomerular basement membrane antibodies in Goodpasture's syndrome and in Wegener's granulomatosis. J Am Soc Nephrol 1992; 2:1227.</a></li><li><a class="nounderline abstract_t">Levy JB, Hammad T, Coulthart A, et al. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int 2004; 66:1535.</a></li><li><a class="nounderline abstract_t">Yang G, Tang Z, Chen Y, et al. Antineutrophil cytoplasmic antibodies (ANCA) in Chinese patients with anti-GBM crescentic glomerulonephritis. Clin Nephrol 2005; 63:423.</a></li><li><a class="nounderline abstract_t">McAdoo SP, Tanna A, Hrušková Z, et al. Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney Int 2017; 92:693.</a></li><li><a class="nounderline abstract_t">Choi HK, Merkel PA, Walker AM, Niles JL. Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis Rheum 2000; 43:405.</a></li><li><a class="nounderline abstract_t">Pendergraft WF 3rd, Niles JL. Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis. Curr Opin Rheumatol 2014; 26:42.</a></li><li><a class="nounderline abstract_t">Gaskin G, Thompson EM, Pusey CD. Goodpasture-like syndrome associated with anti-myeloperoxidase antibodies following penicillamine treatment. Nephrol Dial Transplant 1995; 10:1925.</a></li><li><a class="nounderline abstract_t">Nanke Y, Akama H, Terai C, Kamatani N. Rapidly progressive glomerulonephritis with D-penicillamine. Am J Med Sci 2000; 320:398.</a></li><li><a class="nounderline abstract_t">Bienaimé F, Clerbaux G, Plaisier E, et al. D-Penicillamine-induced ANCA-associated crescentic glomerulonephritis in Wilson disease. Am J Kidney Dis 2007; 50:821.</a></li><li><a class="nounderline abstract_t">Feriozzi S, Muda AO, Gomes V, et al. Cephotaxime-associated allergic interstitial nephritis and MPO-ANCA positive vasculitis. Ren Fail 2000; 22:245.</a></li><li><a class="nounderline abstract_t">Sakai N, Wada T, Shimizu M, et al. Tubulointerstitial nephritis with anti-neutrophil cytoplasmic antibody following indomethacin treatment. Nephrol Dial Transplant 1999; 14:2774.</a></li><li><a class="nounderline abstract_t">Deshayes S, Dolladille C, Dumont A, et al. A Worldwide Pharmacoepidemiologic Update on Drug-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in the Era of Targeted Therapies. Arthritis Rheumatol 2022; 74:134.</a></li><li><a class="nounderline abstract_t">Ahmad YK, Tawfeek S, Sharaf-Eldin M, et al. Anti-Nuclear Cytoplasmic Antibody-Associated Vasculitis: A Probable Adverse Effect of Sofosbuvir Treatment in Chronic Hepatitis C Patients. Hosp Pharm 2017; 52:294.</a></li><li><a class="nounderline abstract_t">Short AK, Lockwood CM. Antigen specificity in hydralazine associated ANCA positive systemic vasculitis. QJM 1995; 88:775.</a></li><li><a class="nounderline abstract_t">Al-Abdouh A, Siyal AM, Seid H, et al. Hydralazine-induced antineutrophil cytoplasmic antibody-associated vasculitis with pulmonary-renal syndrome: a case report. J Med Case Rep 2020; 14:47.</a></li><li><a class="nounderline abstract_t">Santoriello D, Bomback AS, Kudose S, et al. Anti-neutrophil cytoplasmic antibody associated glomerulonephritis complicating treatment with hydralazine. Kidney Int 2021; 100:440.</a></li><li><a class="nounderline abstract_t">Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363:211.</a></li><li><a class="nounderline abstract_t">Walsh M, Merkel PA, Peh CA, et al. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials 2013; 14:73.</a></li><li><a class="nounderline abstract_t">Gunton JE, Stiel J, Clifton-Bligh P, et al. Prevalence of positive anti-neutrophil cytoplasmic antibody (ANCA) in patients receiving anti-thyroid medication. Eur J Endocrinol 2000; 142:587.</a></li><li><a class="nounderline abstract_t">Slot MC, Links TP, Stegeman CA, Tervaert JW. Occurrence of antineutrophil cytoplasmic antibodies and associated vasculitis in patients with hyperthyroidism treated with antithyroid drugs: A long-term followup study. Arthritis Rheum 2005; 53:108.</a></li><li><a class="nounderline abstract_t">Lam DC, Lindsay RH. Accumulation of 2-[14C]propylthiouracil in human polymorphonuclear leukocytes. Biochem Pharmacol 1979; 28:2289.</a></li><li><a class="nounderline abstract_t">Lee E, Hirouchi M, Hosokawa M, et al. Inactivation of peroxidases of rat bone marrow by repeated administration of propylthiouracil is accompanied by a change in the heme structure. Biochem Pharmacol 1988; 37:2151.</a></li><li><a class="nounderline abstract_t">Elkayam O, Levartovsky D, Brautbar C, et al. Clinical and immunological study of 7 patients with minocycline-induced autoimmune phenomena. Am J Med 1998; 105:484.</a></li><li><a class="nounderline abstract_t">Culver B, Itkin A, Pischel K. Case report and review of minocycline-induced cutaneous polyarteritis nodosa. Arthritis Rheum 2005; 53:468.</a></li><li><a class="nounderline abstract_t">Sethi S, Sahani M, Oei LS. ANCA-positive crescentic glomerulonephritis associated with minocycline therapy. Am J Kidney Dis 2003; 42:E27.</a></li><li><a class="nounderline abstract_t">Dunphy J, Oliver M, Rands AL, et al. Antineutrophil cytoplasmic antibodies and HLA class II alleles in minocycline-induced lupus-like syndrome. Br J Dermatol 2000; 142:461.</a></li><li><a class="nounderline abstract_t">Schaffer JV, Davidson DM, McNiff JM, Bolognia JL. Perinuclear antineutrophilic cytoplasmic antibody-positive cutaneous polyarteritis nodosa associated with minocycline therapy for acne vulgaris. J Am Acad Dermatol 2001; 44:198.</a></li><li><a class="nounderline abstract_t">Elkayam O, Yaron M, Caspi D. Minocycline-induced autoimmune syndromes: an overview. Semin Arthritis Rheum 1999; 28:392.</a></li><li><a class="nounderline abstract_t">McGrath MM, Isakova T, Rennke HG, et al. Contaminated cocaine and antineutrophil cytoplasmic antibody-associated disease. Clin J Am Soc Nephrol 2011; 6:2799.</a></li><li><a class="nounderline abstract_t">Gross RL, Brucker J, Bahce-Altuntas A, et al. A novel cutaneous vasculitis syndrome induced by levamisole-contaminated cocaine. Clin Rheumatol 2011; 30:1385.</a></li><li><a class="nounderline abstract_t">Chung C, Tumeh PC, Birnbaum R, et al. Characteristic purpura of the ears, vasculitis, and neutropenia--a potential public health epidemic associated with levamisole-adulterated cocaine. J Am Acad Dermatol 2011; 65:722.</a></li><li><a class="nounderline abstract_t">Ullrich K, Koval R, Koval E, et al. Five consecutive cases of a cutaneous vasculopathy in users of levamisole-adulterated cocaine. J Clin Rheumatol 2011; 17:193.</a></li><li><a class="nounderline abstract_t">Carlson AQ, Tuot DS, Jen KY, et al. Pauci-immune glomerulonephritis in individuals with disease associated with levamisole-adulterated cocaine: a series of 4 cases. Medicine (Baltimore) 2014; 93:290.</a></li><li><a class="nounderline abstract_t">Subesinghe S, van Leuven S, Yalakki L, et al. Cocaine and ANCA associated vasculitis-like syndromes - A case series. Autoimmun Rev 2018; 17:73.</a></li><li><a class="nounderline abstract_t">Krischock L, Pannila P, Kennedy SE. Levamisole and ANCA positivity in childhood nephrotic syndrome. Pediatr Nephrol 2021; 36:1795.</a></li><li><a class="nounderline abstract_t">Kitahara T, Hiromura K, Sugawara M, et al. A case of cimetidine-induced acute tubulointerstitial nephritis associated with antineutrophil cytoplasmic antibody. Am J Kidney Dis 1999; 33:E7.</a></li><li><a class="nounderline abstract_t">Terjung B, Spengler U, Sauerbruch T, Worman HJ. "Atypical p-ANCA" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology 2000; 119:310.</a></li><li><a class="nounderline abstract_t">Locht H, Skogh T, Wiik A. Characterisation of autoantibodies to neutrophil granule constituents among patients with reactive arthritis, rheumatoid arthritis, and ulcerative colitis. Ann Rheum Dis 2000; 59:898.</a></li><li><a class="nounderline abstract_t">Zhao MH, Jayne DR, Ardiles LG, et al. Autoantibodies against bactericidal/permeability-increasing protein in patients with cystic fibrosis. QJM 1996; 89:259.</a></li><li><a class="nounderline abstract_t">Lachenal F, Nkana K, Nove-Josserand R, et al. Prevalence and clinical significance of auto-antibodies in adults with cystic fibrosis. Eur Respir J 2009; 34:1079.</a></li><li><a class="nounderline abstract_t">Carlsson M, Eriksson L, Pressler T, et al. Autoantibody response to BPI predict disease severity and outcome in cystic fibrosis. J Cyst Fibros 2007; 6:228.</a></li><li><a class="nounderline abstract_t">Weiss J, Olsson I. Cellular and subcellular localization of the bactericidal/permeability-increasing protein of neutrophils. Blood 1987; 69:652.</a></li><li><a class="nounderline abstract_t">Choi HK, Lamprecht P, Niles JL, et al. Subacute bacterial endocarditis with positive cytoplasmic antineutrophil cytoplasmic antibodies and anti-proteinase 3 antibodies. Arthritis Rheum 2000; 43:226.</a></li><li><a class="nounderline abstract_t">Chirinos JA, Corrales-Medina VF, Garcia S, et al. Endocarditis associated with antineutrophil cytoplasmic antibodies: a case report and review of the literature. Clin Rheumatol 2007; 26:590.</a></li><li><a class="nounderline abstract_t">Mahr A, Batteux F, Tubiana S, et al. Brief report: prevalence of antineutrophil cytoplasmic antibodies in infective endocarditis. Arthritis Rheumatol 2014; 66:1672.</a></li><li><a class="nounderline abstract_t">Ai S, Liu X, Chen G, et al. Characteristics and Diagnostic Challenge of Antineutrophil Cytoplasmic Antibody Positive Infective Endocarditis. Am J Med 2022; 135:1371.</a></li><li><a class="nounderline abstract_t">Uppal NN, Kello N, Shah HH, et al. De Novo ANCA-Associated Vasculitis With Glomerulonephritis in COVID-19. Kidney Int Rep 2020; 5:2079.</a></li><li><a class="nounderline abstract_t">Anderegg MA, Liu M, Saganas C, et al. De novo vasculitis after mRNA-1273 (Moderna) vaccination. Kidney Int 2021; 100:474.</a></li><li><a class="nounderline abstract_t">Sekar A, Campbell R, Tabbara J, Rastogi P. ANCA glomerulonephritis after the Moderna COVID-19 vaccination. Kidney Int 2021; 100:473.</a></li><li><a class="nounderline abstract_t">Faruqi S, Kastelik JA, McGivern DV. Diagnostic pitfall: Mycobacterium avium complex pulmonary infection and positive ANCA. Eur J Intern Med 2008; 19:216.</a></li><li><a class="nounderline abstract_t">Sherkat R, Mostafavizadeh K, Zeydabadi L, et al. Antineutrophil cytoplasmic antibodies in patients with pulmonary tuberculosis. Iran J Immunol 2011; 8:52.</a></li><li><a class="nounderline abstract_t">Lima I, Oliveira RC, Cabral MS, et al. Anti-PR3 and anti-MPO antibodies are not present in sera of patients with pulmonary tuberculosis. Rheumatol Int 2014; 34:1231.</a></li><li><a class="nounderline abstract_t">Vahid B, Wildemore B, Nguyen C, Marik P. Positive C-ANCA and cavitary lung lesion: recurrence of Wegener granulomatosis or aspergillosis? South Med J 2006; 99:753.</a></li><li><a class="nounderline abstract_t">Cho C, Asuncion A, Tatum AH. False-positive antineutrophil cytoplasmic antibody in aspergillosis with oxalosis. Arch Pathol Lab Med 1995; 119:558.</a></li><li><a class="nounderline abstract_t">Bajema IM, Hagen EC. Evolving concepts about the role of antineutrophil cytoplasm autoantibodies in systemic vasculitides. Curr Opin Rheumatol 1999; 11:34.</a></li><li><a class="nounderline abstract_t">Bauer A, Jabs WJ, Süfke S, et al. Vasculitic purpura with antineutrophil cytoplasmic antibody-positive acute renal failure in a patient with Streptococcus bovis case and Neisseria subflava bacteremia and subacute endocarditis. Clin Nephrol 2004; 62:144.</a></li><li><a class="nounderline abstract_t">Trimarchi M, Gregorini G, Facchetti F, et al. Cocaine-induced midline destructive lesions: clinical, radiographic, histopathologic, and serologic features and their differentiation from Wegener granulomatosis. Medicine (Baltimore) 2001; 80:391.</a></li><li><a class="nounderline abstract_t">Wiesner O, Russell KA, Lee AS, et al. Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not autoimmune vasculitis. Arthritis Rheum 2004; 50:2954.</a></li><li><a class="nounderline abstract_t">Hermann J, Demel U, Stünzner D, et al. Clinical interpretation of antineutrophil cytoplasmic antibodies: parvovirus B19 infection as a pitfall. Ann Rheum Dis 2005; 64:641.</a></li><li><a class="nounderline abstract_t">Fayaz A, Pirson Y, Cosyns JP, et al. Pauci-immune necrotizing and crescentic glomerulonephritis in a patient with systemic lupus erythematosus. Clin Nephrol 2008; 69:290.</a></li></ol></div><div id="topicVersionRevision">Topic 3060 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6297657" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2857806" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2453802" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2155342" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16263885" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8841439" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA). A report on the second phase of an international cooperative study on the standardization of ANCA assays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9507222" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28905856" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9507231" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Diagnostic predictive value of ANCA serology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1655091" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Antigen-specific radioimmunoassays for anti-neutrophil cytoplasmic antibodies in the diagnosis of rapidly progressive glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9163287" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18287252" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Necrotizing and crescentic lupus nephritis with antineutrophil cytoplasmic antibody seropositivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14585921" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis: first results from a multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15210387" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The antineutrophil cytoplasmic antibody-associated vasculitides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9751084" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Antineutrophil cytoplasmic antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10088763" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12840090" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26297628" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23023777" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3574116" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Severe glomerulonephritis with late emergence of classic Wegener's granulomatosis. Report of 4 cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8296613" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : ANCA in systemic vasculitides, collagen vascular diseases, rheumatic disorders and inflammatory bowel diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8410089" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Anti-myeloperoxidase antibodies in Churg-Strauss syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9990352" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12967693" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16142760" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16632015" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Renal involvement in Churg-Strauss syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34032390" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Clinical Manifestations and Long-Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2179617" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9071706" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Comparison of anti-GBM antibodies in sera with or without ANCA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1317224" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Antineutrophil-cytoplasmic antibodies and antiglomerular basement membrane antibodies in Goodpasture's syndrome and in Wegener's granulomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15458448" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Clinical features and outcome of patients with both ANCA and anti-GBM antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15960143" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Antineutrophil cytoplasmic antibodies (ANCA) in Chinese patients with anti-GBM crescentic glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28506760" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10693882" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24276086" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8592607" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Goodpasture-like syndrome associated with anti-myeloperoxidase antibodies following penicillamine treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11149553" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Rapidly progressive glomerulonephritis with D-penicillamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17954295" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : D-Penicillamine-induced ANCA-associated crescentic glomerulonephritis in Wilson disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10803769" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Cephotaxime-associated allergic interstitial nephritis and MPO-ANCA positive vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10534532" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Tubulointerstitial nephritis with anti-neutrophil cytoplasmic antibody following indomethacin treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34164938" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A Worldwide Pharmacoepidemiologic Update on Drug-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in the Era of Targeted Therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28515509" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Anti-Nuclear Cytoplasmic Antibody-Associated Vasculitis: A Probable Adverse Effect of Sofosbuvir Treatment in Chronic Hepatitis C Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8542262" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Antigen specificity in hydralazine associated ANCA positive systemic vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32290867" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Hydralazine-induced antineutrophil cytoplasmic antibody-associated vasculitis with pulmonary-renal syndrome: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33857570" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Anti-neutrophil cytoplasmic antibody associated glomerulonephritis complicating treatment with hydralazine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20647198" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23497590" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10822221" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Prevalence of positive anti-neutrophil cytoplasmic antibody (ANCA) in patients receiving anti-thyroid medication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15696557" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Occurrence of antineutrophil cytoplasmic antibodies and associated vasculitis in patients with hyperthyroidism treated with antithyroid drugs: A long-term followup study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/497011" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Accumulation of 2-[14C]propylthiouracil in human polymorphonuclear leukocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2837228" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Inactivation of peroxidases of rat bone marrow by repeated administration of propylthiouracil is accompanied by a change in the heme structure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9870833" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Clinical and immunological study of 7 patients with minocycline-induced autoimmune phenomena.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15934105" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Case report and review of minocycline-induced cutaneous polyarteritis nodosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12900849" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : ANCA-positive crescentic glomerulonephritis associated with minocycline therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10735951" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Antineutrophil cytoplasmic antibodies and HLA class II alleles in minocycline-induced lupus-like syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11174376" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Perinuclear antineutrophilic cytoplasmic antibody-positive cutaneous polyarteritis nodosa associated with minocycline therapy for acne vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10406406" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Minocycline-induced autoimmune syndromes: an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21980179" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Contaminated cocaine and antineutrophil cytoplasmic antibody-associated disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21706168" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A novel cutaneous vasculitis syndrome induced by levamisole-contaminated cocaine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21658797" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Characteristic purpura of the ears, vasculitis, and neutropenia--a potential public health epidemic associated with levamisole-adulterated cocaine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21617558" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Five consecutive cases of a cutaneous vasculopathy in users of levamisole-adulterated cocaine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25398064" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Pauci-immune glomerulonephritis in individuals with disease associated with levamisole-adulterated cocaine: a series of 4 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29108823" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Cocaine and ANCA associated vasculitis-like syndromes - A case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33484340" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Levamisole and ANCA positivity in childhood nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10074607" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A case of cimetidine-induced acute tubulointerstitial nephritis associated with antineutrophil cytoplasmic antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10930366" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : "Atypical p-ANCA" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11053069" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Characterisation of autoantibodies to neutrophil granule constituents among patients with reactive arthritis, rheumatoid arthritis, and ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8733512" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Autoantibodies against bactericidal/permeability-increasing protein in patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19443536" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Prevalence and clinical significance of auto-antibodies in adults with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17166780" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Autoantibody response to BPI predict disease severity and outcome in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3801674" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Cellular and subcellular localization of the bactericidal/permeability-increasing protein of neutrophils.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10643719" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Subacute bacterial endocarditis with positive cytoplasmic antineutrophil cytoplasmic antibodies and anti-proteinase 3 antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16440133" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Endocarditis associated with antineutrophil cytoplasmic antibodies: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24497495" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Brief report: prevalence of antineutrophil cytoplasmic antibodies in infective endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35820459" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Characteristics and Diagnostic Challenge of Antineutrophil Cytoplasmic Antibody Positive Infective Endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32839744" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : De Novo ANCA-Associated Vasculitis With Glomerulonephritis in COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34087251" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : De novo vasculitis after mRNA-1273 (Moderna) vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34081948" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : ANCA glomerulonephritis after the Moderna COVID-19 vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18395168" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Diagnostic pitfall: Mycobacterium avium complex pulmonary infection and positive ANCA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21427496" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Antineutrophil cytoplasmic antibodies in patients with pulmonary tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24719228" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Anti-PR3 and anti-MPO antibodies are not present in sera of patients with pulmonary tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16866059" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Positive C-ANCA and cavitary lung lesion: recurrence of Wegener granulomatosis or aspergillosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7605176" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : False-positive antineutrophil cytoplasmic antibody in aspergillosis with oxalosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9894628" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Evolving concepts about the role of antineutrophil cytoplasm autoantibodies in systemic vasculitides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15356972" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Vasculitic purpura with antineutrophil cytoplasmic antibody-positive acute renal failure in a patient with Streptococcus bovis case and Neisseria subflava bacteremia and subacute endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11704715" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Cocaine-induced midline destructive lesions: clinical, radiographic, histopathologic, and serologic features and their differentiation from Wegener granulomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15457464" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not autoimmune vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15485998" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Clinical interpretation of antineutrophil cytoplasmic antibodies: parvovirus B19 infection as a pitfall.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18397704" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Pauci-immune necrotizing and crescentic glomerulonephritis in a patient with systemic lupus erythematosus.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
